Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oligonucleotides and methods for treating neurological diseases

A technology of oligonucleotides and nucleotides, applied in nervous system diseases, biochemical equipment and methods, gene therapy, etc., can solve problems such as early polyadenylation

Pending Publication Date: 2022-05-27
QURALIS CORP
View PDF34 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cryptic exons in the STMN2 pre-mRNA contain cryptic polyadenylation sequences that lead to premature polyadenylation of the pre-mRNA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oligonucleotides and methods for treating neurological diseases
  • Oligonucleotides and methods for treating neurological diseases
  • Oligonucleotides and methods for treating neurological diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0486] Example 1: Initial design and selection of STMN2 antisense oligonucleotides

[0487] Antisense oligonucleotides complementary to STMN2 RNA were designed and tested to identify STMN2 antisense oligonucleotides (AONs) capable of acting as inhibitors of STMN2 transcripts including cryptic exons.

[0488] Figures 1A-1C Portions of the STMN2 transcript and STMN2 antisense oligonucleotides designed to target certain portions of the STMN2 transcript are depicted. Specifically, regions of the STMN2 transcript include branch points (eg, branch points 1, 2, and 3), 3' splice acceptor regions, ESE binding regions, TDP43 binding sites, and PolyA regions. STMN2 antisense oligonucleotides were identified based on the position of the STMN2 transcript to which the STMN2 antisense oligonucleotides correspond. E.g, Figure 1A STMN2 antisense oligonucleotides targeting positions 36 to 60 of the STMN2 transcript, including branch point 1, are depicted. Similarly, different STMN2 antise...

Embodiment 2

[0495] Example 2: Method for evaluating STMN2 antisense oligonucleotides

[0496] STMN2 antisense oligonucleotides were evaluated in SY5Y cells and human motor neurons. Specifically, Examples 3, 4 and 5 below describe the results resulting from the evaluation of STMN2 antisense oligonucleotides in SY5Y cells. Examples 6 and 7 below describe the results resulting from the evaluation of STMN2 antisense oligonucleotides in human motor neurons.

[0497] STMN2 antisense oligonucleotides were evaluated in SY5Y cells. Cells were plated in 6- or 96-well plates and grown to 80% confluence. Antisense oligonucleotides (AON) to TDP43 were transfected with RNAiMax (Thermo Fisher Scientific, Waltham, MA, USA) to express the cryptic exon, thereby preventing transcription of the full-length STMN2 (STMN2-FL) product. Vehicle was treated with RNAiMax alone. Positive controls included cells treated with TDP43 siRNA alone ("siRNA TDP43") and / or TDP43 AON alone ("AON TDP43" or "TDP43 AON"). s...

Embodiment 3

[0517] Example 3: STMN2 antisense oligonucleotides restore full-length STMN2 and reduce STMN2 transcripts with cryptic exons in SY5Y cells

[0518] Figure 1B and 1C demonstrated the effectiveness of STMN2 AONs targeting distinct regions of the STMN2 transcript with cryptic exons. Particularly, Figure 1B STMN2 AONs designed and evaluated in SY5Y cells are described. Figure 1C STMN2 AONs designed and evaluated in human motor neurons are depicted. STMN2 AONs represented by solid lines produced cells with more than 50% increased STMN2-FL mRNA expression compared to TDP43 AONs treated alone. STMN2 AONs represented by dashed lines produced cells with less than 50% increased STMN2-FL (full length) mRNA compared to TDP43 AONs treated alone.

[0519] about figure 2 , when treated with 500 nM TDP43 AON, TDP43 transcripts were reduced by ~52% and STMN2-FL by ~57%. 500 nM treatment of STMN2 AON with SEQ ID NO:36 increased TDP43 levels by 25% and STMN-FL levels by 55% (rescue to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are antisense oligonucleotide sequences, and methods for treating neurological diseases. Oligonucleotide inhibitors are described herein. In various embodiments, oligonucleotides target transcripts to treat neurological diseases, including motor neuron diseases and / or neurological diseases. For example, inhibitors of transcripts may be used to treat PD, ALS, FTD, and ALS with FTD.

Description

[0001] cross reference [0002] This application claims US Provisional Patent Application No. 62 / 856,264, filed June 3, 2019; US Provisional Patent Application No. 62 / 914,252, filed October 11, 2019; and US Provisional Patent Application No. 62 / 914,252, filed December 18, 2019 The benefit of and priority to Patent Application No. 62 / 949,817, the entire disclosure of each of which is hereby incorporated by reference in its entirety for all purposes. [0003] sequence listing [0004] This application contains a Sequence Listing, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy was created on May 29, 2020, named QRL-002WO_SL.txt, and is 378,978 bytes in size. [0005] Field of Invention [0006] The present application relates to inhibitors of STMN2 transcripts including cryptic exons, including STMN2 antisense oligonucleotide sequences, and methods of treating neurological disorders. [0007] Backg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/125A61K31/712C12N15/113
CPCC12N15/113C12N2310/11C12N2310/14C12N2310/341C12N2320/31C12N2320/33C12N2320/11C12N2310/346C12N2310/3341C12N2310/315A61K45/06Y02A50/30C12N2310/321C12N2310/3525A61K31/713A61K48/00A61P25/00A61K9/0053
Inventor S.辛克利D.布朗S.阿格拉瓦尔
Owner QURALIS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com